Evidence suggesting the use of adult stem cells as a viable treatment for myocardial infarction continues to mount. In this issue of the Journal of Molecular and Cellular Cardiology, Mills et al present compelling evidence that suggests mesenchymal stem cells (MSCs), when used to treat myocardial infarction, are not pro-arrhythmic and may actually help sustain the action potentials in myocytes surviving in the border zone and infarcted region. These findings stand in stark contrast to the failure of skeletal myoblasts (SKMBs) to propagate an action potential to those same regions, although both cell types appear to confer similar recovery of mechanical function in a rat myocardial infarction model. The main conclusions of the study are that (1) both approaches successfully improve mechanical function as compared to saline injection, (2) SKMBs increase the susceptibility to and incidence of ventricular tachycardia or fibrillation while the MSCs may decrease these serious electrical outcomes, (3) that the SKMBs exist as isolated islands with no gap junctional coupling to adjacent cells, while the MSCs effectively integrate into the cardiac syncytium, and (4) the amplitude of the action potential (AP) recorded by optical techniques in the presence of SKMBs shows a decrement similar to that observed in the presence of saline, while MSCs reduce this decrement in AP amplitude.Some of these results are not surprising. Both in vitro studies [7] and human trials [8] have shown the propensity of SKMBs to induce arrhythmias while exerting mechanical benefit. Further, preliminary in vivo studies in animals and humans have shown that MSCs also can be mechanically beneficial [9][10][11]. However, whether this restoration of pump function is due to a change in the passive or contractile properties of the infarct is currently unknown. As SKMBs do not make electrical connections with the native myocardium, it is unlikely that they contract in synchrony with the rest of the heart. Thus, the improved mechanical function induced by SKMBs is likely due to a change in passive mechanical properties of the infarct leading to improved diastolic function. The same may be true with MSCs. However, the action potential recordings in Figure 4 of Mills et al., suggest the presence of cells with excitable membranes (as documented by the rapid upstroke in the MSC-treated group) in the infarct region. Therefore, MSCs may contribute to both passive and active contractile improvements in function. Further studies using techniques to determine regional diastolic and systolic function in the infarct region are needed to answer this question.Corresponding author: Ira S. Cohen, M.D., Ph.D., Department of Physiology and Biophysics, Basic Science Tower, T-6, Room 153B, Stony Brook University, Stony Brook, NY 11794-8661. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, ty...